PhaseBio Pharmaceuticals Inc. (PHAS) Prices 16M Share Common Offering at $3.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/10/2026
- S&P 500, Dow futures attempt recovery ahead of inflation report
- Oracle raises full year profit guidance, stock rises after hours
- Oil surges 6%, Brent and US crude both surpass $100 on more tanker attacks
- Analysts split on Apple after foldable iPhone Duo debut
- JPMorgan upgrades Meta on AI models and agents, sees 'meaningful headroom'
- S&P 500 ends down as oil tops $100 per barrel
- White House copper tariff plan stalls amid affordability concerns, sources say
- Trump promises $5,000 payout to U.S. adults if Republicans win election
- Crude Inventory 0.4M Barrels Last Week - EIA
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
PhaseBio Pharmaceuticals Inc. (PHAS) to Offer Common Stock
March 17, 2021 5:02 PM EDTPhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) announced that it has commenced an underwritten public offering of shares of its common stock. In addition, PhaseBio expects to grant the underwriters a 30-day option to purchase additional shares of its common stock. All of... More
PhaseBio Pharmaceuticals Inc. (PHAS) PT Raised to 'Street High' $19 at Needham & Company
March 16, 2021 10:44 AM EDTNeedham & Company analyst Chad Messer raised the price target on PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) a 'Street High' to $19.00 (from $18.00) while maintaining a Buy rating.
... MorePhaseBio Pharmaceuticals Inc. (PHAS) Halted on LUDP, Up 12%
March 16, 2021 10:42 AM EDTPhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) Halted on LUDP, Up 12%
